Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net loss	$ (5,422,693)	$ (650,974)
Non-cash items included in net loss:
Depreciation and amortization	87,375	76,875
Change in fair value of common stock warrant liability	(3,026)	(4,280,297)
Deferred revenue	(125,000)	(125,000)
Stock-based compensation	607,230	263,192
Treasury shares issued for services and 401(k) matching contribution	9,323	20,835
Change in deferred rent liability	(5,186)	(3,829)
Deferred finance charges	89,675	31,560
Net changes in:
Deposits, advances, other current assets and other assets	(229,200)	(225,660)
Accounts payable	649,577	1,841,037
Accrued liabilities	(501,815)	(157,534)
Cash received for non-refundable research and development fee		5,000,000
Net cash (used in) provided by operating activities:	(4,843,740)	1,790,205
Cash flows from investing activities:
Purchases of investment securities	(17,862,837)	(20,245,204)
Proceeds from sale and maturity of investment securities	7,780,000	3,048,000
Net cash used in investing activities	(10,082,837)	(17,197,204)
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs	13,825,231	6,711,173
Proceeds from sale of preferred stock, net of issuance costs		13,648,663
Proceeds from exercise of options to purchase common stock		174,871
Principal payments on notes payable	(10,891)	(14,461)
Net cash provided by financing activities	13,814,340	20,782,190
Decrease in cash and cash equivalents	(1,112,237)	(5,375,191)
Cash and cash equivalents at beginning of period	5,718,504	14,991,488
Cash and cash equivalents at end of period	4,606,267	20,366,679
Supplemental disclosures of cash flow information:
Interest paid	141,038	180,928
Common Stock Warrants (Member)
Cash flows from financing activities:
Proceeds from exercise of common stock warrants		$ 261,944